125 completed, 25 recruiting, 20 terminated, 17 unknown. 210 Phase 1, 63 Phase 2.
Follow Cranial Nerve Diseases: new trials by email Literature Review of Cranial Nerve Diseases trials Research Report on Cranial Nerve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After Trauma 4-Aminopyridine - Vocal Cord Paralysis, Recurrent Laryngeal Nerve Palsy | Phase 1 | Not yet recruiting | Milton S. Hershey Medical Center | 50 | 2026-12-01 | 2026-09-21 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 156 | 2026-10-07 | 2026-11-13 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia RP-008, Varenicline tartrate - Trigeminal Neuralgia | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 24 | 2026-09-10 | 2026-10-23 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy Nicotinamide treatment - Leber Hereditary Optic Neuropathy (LHON), Leber's Hereditary Optic Neuropathy (LHON) | Phase 1 | Not yet recruiting | University Hospital, Angers | 13 | 2026-04-01 | 2025-12-18 |
| Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) ER-100 epigenetic therapy - Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) | Phase 1 | Recruiting | Life Biosciences Inc. | 18 | 2026-03-02 | 2026-05-19 |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 1 | Not yet recruiting | Huashan Hospital | 15 | 2026-02-01 | 2026-01-15 |
| Home-based Vision Therapy Virtual-reality convergence training game - Convergence Insufficiency | Phase 1 | Recruiting | VA Office of Research and Development | 45 | 2026-01-14 | 2026-01-20 |
| Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies ARO-MAPT-SC, Placebo - Alzheimer Disease, Tauopathies | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 160 | 2025-11-18 | 2026-11-10 |
| Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1 / Phase 2 | Recruiting | PYC Therapeutics | 24 | 2025-09-30 | 2026-06-29 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders | Phase 1 | Recruiting | TG Therapeutics, Inc. | 100 | 2025-05-06 | 2026-10-27 |
Showing 20 of 210. Sign in to see all of them.
Astrocytoma (49) · Optic Nerve Glioma (48) · Medulloblastoma (46) · Familial ependymoma (40) · Oligodendroglioma (36) · Choroid Plexus Neoplasms (34) · Neuromyelitis Optica (32) · Central Nervous System Neoplasms (31) · Esthesioneuroblastoma, Olfactory (29) · Squamous Cell Carcinoma of Head and Neck (23) · Supranuclear Palsy, Progressive (23) · Salivary Gland Neoplasms (21) · Carcinoma, Non-Small-Cell Lung (17) · Neuroblastoma (17) · Neuroectodermal Tumors, Primitive, Peripheral (17)
Nervous System Diseases (210) · Eye Diseases (148) · Optic Nerve Diseases (110) · Neoplasms by Site (96) · Neoplasms (91) · Neoplasms by Histologic Type (86) · Neoplasms, Nerve Tissue (86) · Neuroectodermal Tumors (86) · Neoplasms, Germ Cell and Embryonal (85) · Central Nervous System Diseases (81) · Neoplasms, Glandular and Epithelial (79) · Neoplasms, Neuroepithelial (76) · Brain Diseases (71) · Nervous System Neoplasms (70)
Filgrastim (12) · Carboplatin (9) · Temozolomide (9) · Bevacizumab (6) · Docetaxel (6) · Granulocyte Colony-Stimulating Factor (6) · Cetuximab (4) · Cyclophosphamide (4) · Erlotinib Hydrochloride (4) · Etoposide (4) · Irinotecan (4) · Busulfan (3) · Ifosfamide (3) · Methylprednisolone (3) · O(6)-benzylguanine (3)
National Cancer Institute (NCI) (26) · Pediatric Brain Tumor Consortium (8) · Children's Oncology Group (6) · Biogen (5) · National Institutes of Health Clinical Center (CC) (5) · University of California, San Francisco (5) · Memorial Sloan Kettering Cancer Center (4) · National Eye Institute (NEI) (4) · Tianjin Medical University General Hospital (4) · Case Comprehensive Cancer Center (3) · City of Hope Medical Center (3) · Johns Hopkins University (3) · M.D. Anderson Cancer Center (3) · Alexandria University (2) · Invicro (2)
United States (134) · China (20) · Canada (15) · United Kingdom (12) · Germany (6) · Spain (5) · Australia (4) · Belgium (4) · Iran (4) · Egypt (3) · France (2) · Greece (2) · Israel (2) · New Zealand (2) · Norway (2)
Adam Boxer, MD, PhD (3) · Michael Levy, MD, PhD (3) · Scot C. Remick, MD (3) · Andrew Stephens, MD, PhD (2) · Elizabeth Fox, MD (2) · Erling A Tronvik, PhD, MD (2) · Harry T Whelan, MD (2) · Mai ElBahwash, PhD (2) · Mark W. Kieran, MD, PhD (2) · Susan M. Blaney, MD (2) · Aaron Tward, MD (1)
PMID 10916328, PMID 15033677, PMID 15793381, PMID 15814645, PMID 16234526, PMID 16533779, PMID 16899778, PMID 16914576, PMID 17634493, PMID 17941066, PMID 18048828, PMID 18281544, PMID 18281546, PMID 18470481, PMID 19065567, PMID 19075272, PMID 19430790, PMID 19838774, PMID 20006669, PMID 20044751, PMID 20049936, PMID 20145168, PMID 20407240, PMID 20460632, PMID 20606544, PMID 21115653, PMID 21211990, PMID 21764821, PMID 22236384, PMID 22294344, PMID 23131255, PMID 23554030, PMID 23623397, PMID 23773637, PMID 23857966, PMID 23868427, PMID 24398093, PMID 24438512, PMID 24457989, PMID 25191939, PMID 25223501, PMID 25342621, PMID 25965900, PMID 26062933, PMID 26606867, PMID 26611425, PMID 26933802, PMID 27143789, PMID 27160012, PMID 27631475
U01CA081457 (9), U01CA097452 (8), P30CA043703 (3), 2017 (2), P30CA033572 (2), U01CA062502 (2), U01CA069856 (2), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), P30CA008748 (1), P30CA016087 (1)